A detailed history of Wellington Management Group LLP transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 105,769 shares of ITOS stock, worth $870,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,769
Previous 87,514 20.86%
Holding current value
$870,478
Previous $1.3 Million 16.87%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.09 - $17.97 $184,192 - $328,042
18,255 Added 20.86%
105,769 $1.08 Million
Q2 2024

Aug 13, 2024

BUY
$10.33 - $18.09 $17,147 - $30,029
1,660 Added 1.93%
87,514 $1.3 Million
Q1 2024

May 15, 2024

BUY
$9.89 - $13.64 $849,096 - $1.17 Million
85,854 New
85,854 $1.17 Million
Q1 2023

May 12, 2023

SELL
$13.02 - $22.62 $25,428 - $44,176
-1,953 Reduced 1.3%
148,594 $2.02 Million
Q4 2022

Feb 13, 2023

BUY
$17.77 - $21.6 $499,941 - $607,694
28,134 Added 22.98%
150,547 $2.94 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $329,926 - $483,360
17,738 Added 16.95%
122,413 $2.33 Million
Q1 2022

May 16, 2022

SELL
$31.92 - $47.45 $69,298 - $103,013
-2,171 Reduced 2.03%
104,675 $3.37 Million
Q4 2021

Feb 11, 2022

SELL
$26.23 - $47.86 $3.05 Million - $5.57 Million
-116,454 Reduced 52.15%
106,846 $4.98 Million
Q2 2021

Aug 16, 2021

BUY
$17.9 - $36.1 $3.07 Million - $6.2 Million
171,700 Added 332.75%
223,300 $5.73 Million
Q1 2021

May 17, 2021

SELL
$30.86 - $44.2 $299,342 - $428,740
-9,700 Reduced 15.82%
51,600 $1.76 Million
Q4 2020

Feb 12, 2021

BUY
$21.59 - $33.95 $1.32 Million - $2.08 Million
61,300 New
61,300 $2.07 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.